Key clinical point: Romidepsin and 5-azacytadine showed good activity in peripheral T-cell lymphomas (PTCL).
Major finding: In total, 11 of 16 patients with angioimmunoblastic T-cell lymphoma (AITL) or primary cutaneous follicular helper T-cell lymphoma (PTCL-TFH) had a clinical response.
Study details: A phase 2 open-label trial of 25 patients with PTCL.
Disclosures: Dr. Falchi reported having no financial disclosures. Other investigators reported funding from Celgene, which supported the study.
Falchi L et al. 15-ICML, Abstract 129.